Indiana based Eli Lilly & Co. has said that it will apply for approval to sell its new diabetes insulin to patients next year.
Lilly says that their experimental insulin helped diabetic patients more than Sanofi’s Lantus in controlling patients’ blood sugar.
There are some concerns as three studies showed increases in rates of liver enzymes, and lower rates of good, or HDL, cholesterol, and that could give Lilly some problems gaining FDA approval.
In three trials of over 3,000 patients, Lilly’s insulin was superior to Lantus in controlling blood sugar.
Nearly 30 million people have diabetes in the U.S or about 8 percent of the population.